Zenas BioPharma Reports 95% Lesion Reduction in MoonStone Phase 2 Trial: What’s Next for Obexelimab in Multiple Sclerosis?
Obexelimab Shows Near-Complete Suppression of Inflammatory Brain Lesions
Positive news emerged for multiple sclerosis (MS) research as Zenas BioPharma announced that obexelimab achieved a 95% relative reduction in new gadolinium-enhancing T1 brain lesions compared to placebo in the Phase 2 MoonStone trial. This effect, seen in patients with relapsing multiple sclerosis (RMS), reached statistical significance (p=0.0009) and suggests the therapy’s potential as a disease-modifying agent for patients facing limited treatment choices.
Clinical Data Highlights Significant Impact on Disease Activity
The Phase 2 MoonStone trial enrolled 116 RMS patients and compared obexelimab to placebo over a 12-week, double-blind treatment period. The mean number of new MRI lesions at weeks 8 and 12 for the obexelimab group was nearly zero (0.01), in stark contrast to the placebo group (0.23). Moreover, obexelimab not only curbed acute inflammation but also reduced the cumulative burden of chronic lesions, based on T2 MRI findings.
| Measure | Obexelimab Group | Placebo Group |
|---|---|---|
| Adjusted mean new GdE T1 lesions/scan (Weeks 8-12) | 0.01 (95% CI: 0.00, 0.06) | 0.23 (95% CI: 0.11, 0.51) |
| Relative reduction (Primary Endpoint) | 95% (p=0.0009) | |
Notably, the benefits appeared as early as week 8 and persisted at week 12, with near-complete suppression of active lesions—markers of ongoing inflammation in MS.
Obexelimab’s Safety Profile Remains Consistent
Safety is a key consideration for any new therapy. According to Zenas, obexelimab was well-tolerated, mirroring results from earlier studies. Side effects were typically mild, such as injection site reactions, with no new safety signals reported.
Broad Potential Across Autoimmune Diseases
Obexelimab’s unique design—a monoclonal antibody targeting CD19 and Fc?RIIb—enables it to inhibit pathogenic B cells without depleting them, aiming to halt inflammation while maintaining immune function. With positive results in MS, the drug is being investigated further in diseases like Immunoglobulin G4-Related Disease (Phase 3 INDIGO trial) and systemic lupus erythematosus (Phase 2 SunStone trial), with more data anticipated in late 2025 and mid-2026, respectively.
What’s Next? Upcoming Milestones to Watch
- Q1 2026: 24-week data from MoonStone, which will evaluate long-term efficacy and potential disability progression.
- Year-End 2025: Topline results from Phase 3 INDIGO trial in IgG4-Related Disease.
- Mid-2026: Results from Phase 2 SunStone trial in systemic lupus erythematosus.
- 2026: Launch of new Phase 3 trials for orelabrutinib, another promising Zenas asset in progressive MS subtypes.
Takeaway: Could Obexelimab Redefine Early Intervention in MS?
MS, a chronic CNS disorder with no cure, often results in irreversible disability over time. Early and effective therapy can be critical to preserving neurological function. The MoonStone data underscores the value of targeted, self-administered treatments that address both inflammatory and chronic lesion burden in relapsing MS.
As the community awaits 24-week outcomes and pivotal Phase 3 results, investors and patients alike are watching whether obexelimab could become a cornerstone in the future MS treatment landscape. Will these early successes translate into broader clinical and regulatory breakthroughs? The coming quarters promise crucial updates—and potential shifts in how autoimmune diseases are managed.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI